Title : Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types.

Pub. Date : 2022 Jun 28

PMID : 35358627






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The efficacy/safety of combining palbociclib (a CDK4/6 inhibitor) and sunitinib (a multi-targeted receptor tyrosine kinase inhibitor) was evaluated, using patient-derived xenograft (PDX) models. Sunitinib ret proto-oncogene Homo sapiens